ArticleArchives of rheumatology2024
Relationship between IgA vasculitis and prothrombotic risk factors: A prospective, case-control study.
Article in Archives of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to determine whether there are commonly occurring hematologic causes that may lead to thrombosis in patients recently diagnosed with immunoglobulin A vasculitis (IgAV). Patients and methods: The prospective study enrolled 107 pediatric patients diagnosed with IgAV and 98 healthy age- and sex-matched controls. Patients with IgAV who were treated at a single center between February 2016 and June 2022 were evaluated for the prevalence and clinical relevance of thrombophilic gene mutations and other prothrombotic risk factors, as well as coagulation test indices. The genotypes for common mutations in prothrombin (Pt) G20210A, factor V Leiden (FVL), and methylenetetrahydrofolate reductase (MTHFR) C677T were assessed. The coagulation assays, including Pt time and activated partial thromboplastin time, and the levels of fibrinogen, factor VIII, factor IX, and von Willebrand factor antigen were analyzed. Additionally, the levels of antithrombin, protein C, and free protein S were evaluated during the disease's acute phase before initiation of anti-inflammatory drugs. Results: Seventeen of the 107 IgAV patients were excluded. Consequently, 90 children (36 males, 54 females; mean age: 10.2±3.2 years; range, 3 to 18 years) diagnosed with IgAV and 98 healthy children (45 males, 53 females; mean age: 9.7±3.8 years; range, 2 to 18 years) as a control group were analyzed. A statistical analysis found no significant difference between the groups in terms of indices of coagulation assays and other prothrombotic risk factors (p>0.05). The mutation frequencies of the Pt G20210A, FVL, and MTHFR C677T loci among IgAV patients were not significantly different from the control group (p>0.05). Conclusion: Given there is no predisposition to thrombophilia and IgAV is a form of vasculitis, the cause of thrombosis among patients with IgAV may involve mechanisms related to the inflammationhemostasis cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.